This glossary is a resource to provide definitions for many of the commonly used measures and terms in tables and reports from the 2018 National Survey on Drug Use and Health (NSDUH). Where relevant, cross-references to details in the 2018 NSDUH methodological summary and definitions report also are provided.
For some key terms, specific question wording is provided for clarity. In some situations, information also is included about specific gate questions. In many instances, a gate question is the first question in a series of related questions. How a respondent answers the gate question affects whether the respondent is asked additional questions in that section of the interview or is routed to the next section of the interview. In some sections of the interview, respondents may be asked more than one gate question to determine whether they are asked additional questions in that section or are routed to the next section.1
Because of changes to the 2015 questionnaire, estimates for several measures in 2015 onward are not comparable with those from 2014 or prior years, even if the basic definitions may be the same or similar to those from prior years. Definitions corresponding to measures affected by questionnaire changes due to the partial questionnaire redesign in 2015 or other questionnaire changes since 2015 are starred with an asterisk (*). Definitions completely new since 2015 because of the questionnaire changes are indicated by a dagger symbol (†). See Section C in the methodological summary and definitions report for the 2015 NSDUH for details about the questionnaire changes in 2015 and their effects on comparability of estimates between 2015 and prior years.2
2 See the following reference: Center for Behavioral Health Statistics and Quality. (2016). 2015 National Survey on Drug Use and Health: Methodological summary and definitions. Retrieved from https://www.samhsa.gov/data/
3 See the following reference: American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (DSM-IV) (4th ed.). Washington, DC: Author.
6 See the following reference: Office of Management and Budget. (1997). Revisions to the standards for the classification of federal data on race and ethnicity. Federal Register, 62(210), 58781-58790.
14 These codes are updated approximately every 10 years and are available at https://www.ers.usda.gov/topics/rural-economy-population/rural-classifications.aspx by clicking on that page's link to the "Rural/Urban Continuum Codes."
17 Respondents in 2002 to 2015 were asked specifically about driving under the influence of "illegal" drugs. However, respondents' perceptions of what constitutes an "illegal" drug may differ depending on the marijuana laws in the states where respondents are living. Therefore, these questions were revised starting with the 2016 NSDUH as indicated in the definition above.
18 See the following reference: Endicott, J., Spitzer, R. L., Fleiss, J. L., & Cohen, J. (1976). The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry, 33, 766-771. https://doi.org/10.1001/archpsyc.1976.01770060086012
26 Starting in 2015, respondents were asked about any use of prescription drugs in the past 12 months or in their lifetime (i.e., not necessarily misuse). However, respondents who reported any use of prescription drugs were not asked when they first used these drugs.
27 See the following reference: Kessler, R. C., Barker, P. R., Colpe, L. J., Epstein, J. F., Gfroerer, J. C., Hiripi, E., Howes, M. J., Normand, S. L., Manderscheid, R. W., Walters, E. E., & Zaslavsky, A. M. (2003). Screening for serious mental illness in the general population. Archives of General Psychiatry, 60, 184-189. https://doi.org/10.1001/archpsyc.60.2.184
28 See the following reference: Leon, A. C., Olfson, M., Portera, L., Farber, L., & Sheehan, D. V. (1997). Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. International Journal of Psychiatry in Medicine, 27(2), 93-105. https://doi.org/10.2190/t8em-c8yh-373n-1uwd
29 See the following reference: Novak, S. P., Colpe, L. J., Barker, P. R., & Gfroerer, J. C. (2010). Development of a brief mental health impairment scale using a nationally representative sample in the USA. International Journal of Methods in Psychiatric Research, 19(Suppl. 1), 49-60.
30 See the following reference: Rehm, J., Üstün, T. B., Saxena, S., Nelson, C. B., Chatterji, S., Ivis, F., & Adlaf, E. (1999). On the development and psychometric testing of the WHO screening instrument to assess disablement in the general population. International Journal of Methods in Psychiatric Research, 8, 110-123. https://doi.org/10.1002/mpr.61
31 See the following reference: American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (DSM-5) (5th ed.). Arlington, VA: Author.
32 See the following reference: Center for Behavioral Health Statistics and Quality. (2012). Results from the 2011 National Survey on Drug Use and Health: Summary of national findings (HHS Publication No. SMA 12-4713, NSDUH Series H-44). Rockville, MD: Substance Abuse and Mental Health Services Administration.
33 See the following reference: Center for Behavioral Health Statistics and Quality. (2018). National Survey on Drug Use and Health: 2017 public use file and codebook. Retrieved from https://datafiles.samhsa.gov/
36 See the following reference: First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (2002). Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition (SCID-I/NP). New York, NY: New York State Psychiatric Institute, Biometrics Research.
37 See the following reference: Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) Reorganization Act, Pub. L. No. 102-321 (1992).
41 See the following reference: Shiffman, S., Hickcox, M., Gnys, M., Paty, J. A., & Kassel, J. D. (1995, March). The Nicotine Dependence Syndrome Scale: Development of a new measure. Poster presented at the annual meeting of the Society for Research on Nicotine and Tobacco, San Diego, CA.
42 See the following reference: Shiffman, S., Waters, A. J., & Hickcox, M. (2004). The Nicotine Dependence Syndrome Scale: A multidimensional measure of nicotine dependence. Nicotine & Tobacco Research, 6, 327-348. https://doi.org/10.1080/1462220042000202481
43 See the following reference: Fagerstrom, K.-O. (1978). Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addictive Behaviors, 3-4, 235-241. https://doi.org/10.1016/0306-4603(78)90024-2
44 See the following reference: Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerstrom, K.-O. (1991). The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction, 86, 1119-1127. https://doi.org/10.1111/j.1360-0443.1991.tb01879.x
53 Respondents were not asked about treatment for prescription pain relievers, prescription tranquilizers, prescription stimulants, or prescription sedatives if they had not misused these substances in their lifetime.
57 More information about the creation of the statistically adjusted SPD variables can be found in the following two references:
Center for Behavioral Health Statistics and Quality. (2012). 2010 National Survey on Drug Use and Health: Methodological resource book (Section 16b, Analysis of effects of 2008 NSDUH questionnaire changes: Methods to adjust adult MDE and SPD estimates and to estimate SMI in the 2005-2009 surveys). Rockville, MD: Substance Abuse and Mental Health Services Administration.
Office of Applied Studies. (2009). Results from the 2008 National Survey on Drug Use and Health: National findings (HHS Publication No. SMA 09-4434, NSDUH Series H-36). Rockville, MD: Substance Abuse and Mental Health Services Administration.
67 Respondents were asked about treatment for depression regardless of whether they were classified as having a major depressive episode (MDE). To produce estimates of treatment for depression among people with MDE, the analysis needs to be restricted to respondents who had a lifetime or past year MDE.